Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Τίτλος | Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., Timotheadou E., Christodoulou C., Pectasides D., Gogas H., Wirtz R. M., Makatsoris T., Bafaloukos D., Aravantinos G., Televantou D., Pavlidis N., & Fountzilas G. |
Journal | Clin Breast Cancer |
Volume | 12 |
Issue | 3 |
Pagination | 183-93 |
Date Published | 2012 Jun |
ISSN | 1938-0666 |
Λέξεις κλειδιά | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Carcinoma, Chemokine CXCL13, Cyclophosphamide, Dose-Response Relationship, Drug, Female, Fluorouracil, Gene Expression Regulation, Neoplastic, Humans, Methotrexate, Middle Aged, Multicenter Studies as Topic, Prognosis, Randomized Controlled Trials as Topic, Receptor, ErbB-2, Receptors, CXCR5, Retrospective Studies, Risk, RNA, Messenger, Treatment Outcome, Up-Regulation, Young Adult |
Abstract | UNLABELLED: The CXCL13-CXCR5 is a chemokine axis that is activated in some breast cancers. A total of 321 tissue blocks from a group of patients who received adjuvant, dose-dense chemotherapy for high-risk early breast cancer were examined. Activation of this axis was found to be associated with determinants of poor prognosis but also with improved outcome in the human epidermal growth factor receptor 2 overexpressing subpopulation. |
DOI | 10.1016/j.clbc.2012.03.006 |
Alternate Journal | Clin Breast Cancer |
PubMed ID | 22607768 |